[HTML][HTML] Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer

K Fujita, Y Kubota, H Ishida, Y Sasaki - World journal of …, 2015 - ncbi.nlm.nih.gov
Irinotecan hydrochloride is a camptothecin derivative that exerts antitumor activity against a
variety of tumors. SN-38 produced in the body by carboxylesterase is the active metabolite of …

Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open …

…, S Iwamoto, K Shimada, Y Komatsu, Y Sasaki… - The lancet …, 2013 - thelancet.com
Background Studies done in Asia have shown that a regimen of S-1 plus oxaliplatin (SOX)
has promising efficacy and safety in patients with metastatic colorectal cancer. We aimed to …

Unpredicted Clinical Pharmacology of UCN-01 Caused by Specific Binding to Human α1-Acid Glycoprotein

…, H Kobayashi, Y Shimada, T Tamura, Y Sasaki… - Cancer Research, 1998 - AACR
The pharmacokinetics of UCN-01 after administration as a 72- or 3-h infusion to cancer
patients in initial Phase I trials displayed distinctive features that could not have been predicted …

Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority …

…, M Tsuda, Y Kurokawa, T Tamura, Y Sasaki… - The lancet …, 2017 - thelancet.com
Background Weekly administration of solvent-based paclitaxel is one of the standard second-line
chemotherapy regimens for advanced gastric cancer. Nanoparticle albumin-bound …

Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion.

T Ohtsu, Y Sasaki, T Tamura, Y Miyata… - Clinical cancer research …, 1995 - AACR
The present study was conducted to compare the pharmacokinetics and pharmacodynamics
(PD) of paclitaxel between Phase I trials of 3- and 24-h infusions and to determine the most …

[HTML][HTML] Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer

T Satoh, KH Lee, SY Rha, Y Sasaki, SH Park… - Gastric cancer, 2015 - Springer
Background This multicenter, randomized phase II trial was conducted to compare the efficacy
and safety of nimotuzumab plus irinotecan (N-IRI) versus irinotecan alone (IRI) in patients …

Genotype‐directed, dose‐finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms

…, T Nishina, S Okamura, T Esaki, Y Sasaki… - Cancer …, 2011 - Wiley Online Library
Irinotecan‐induced severe neutropenia is associated with homozygosity for the UGT1A1*28
or UGT1A1*6 alleles. In this study, we determined the maximum‐tolerated dose (MTD) of …

[HTML][HTML] Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the …

…, N Boku, Y Miyata, H Takiuchi, K Yamaguchi, Y Sasaki… - Gastric Cancer, 2012 - Springer
Background The Trastuzumab for Gastric Cancer (ToGA) study is the first international trial to
include Japanese patients with human epidermal growth factor 2 (HER2) positive advanced…

Toxicities of receptor tyrosine kinase inhibitors in cancer pharmacotherapy: Management with clinical pharmacology

…, H Ishida, Y Kubota, Y Sasaki - Current Drug …, 2017 - ingentaconnect.com
A number of molecularly targeted anticancer drugs that efficiently inhibit receptor tyrosine
kinases, socalled receptor tyrosine kinase inhibitors (TKIs), have been developed. Although …

Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer

…, H Iwasa, Y Okazaki, T Hirose, Y Sasaki - Cancer chemotherapy …, 2010 - Springer
Purpose To investigate the effects of genetic polymorphisms on morphine-induced adverse
events in cancer patients. Methods We examined the relation of morphine-related adverse …